Merck KGaA Enters Deal With BenevolentAI, Exscientia for AI-Based Drug Discovery
By David Sachs Merck KGaA said that it has partnered with BenevolentAI and Exscientia on an initiative to discover more drugs with artificial intelligence, which the company says…
Read more Merck KGaA Enters Deal With BenevolentAI, Exscientia for AI-Based Drug Discovery